In the topical treatment of corticosteroid-responsive dermatoses... Pandel delivers a package of benefits In the topical treatment of corticosteroid-responsive dermatoses... Pandel delivers a package of benefits
Pandel® Cream is a mid-potency steroid
Pandel® Cream is a mid-potency steroid

Clinically proven efficacy in atopic dermatitis*1

Physicians and patients agree: Nearly 70% of physicians and patients rated overall treatment efficacy with Pandel® in atopic dermatitis as “Good or Excellent”1

Pandel® demonstrated progressive symptom improvement in lesion scores vs placebo at each study visit1
  • Day 3 (P=0.0027)
  • Day 7 (P=0.0061)
  • Day 14 (P=0.0001)
Physician and patient assessments of overall treatment efficacy at end of therapy
  • Day 3 (P=0.0027)
  • Day 7 (P=0.0061)
  • Day 14 (P=0.0001)
Hand with Cream Gift

Clinically proven efficacy in psoriasis§1

Pandel® demonstrated significant improvement in psoriasis symptoms by end of week 3ll1
  • Significant improvement in the total lesion score by end of weeks 1 and 3# vs placebo1
  • Significantly more effective in overall improvement by end of week 3ll vs placebo1

The soothing feel of an emollient-based cream2

  • Benefits of an emollient-rich base:
    • Rehydrates the outermost layer of the skin3,4
    • Restores the skin’s suppleness and pliability3,4
Hand feeling shoulder
Applying Pandel® Cream to shoulder

Convenient dosing2

  • Applied to affected area(s) once or twice daily, depending on severity of symptoms2
  • Available in an 80-g tube2
* From a 2-week, double-blind, randomized, multicenter, placebo-controlled study of 168 patients with atopic dermatitis (patients on Pandel®: n=106; patients on placebo: n=62).1
The combined score for infiltration, scaling, erythema, lichenification, vesicles, papules, and excoriation, which were evaluated on a scale of 0 (not present) to 3 (severe).1
P<0.0001 vs placebo.1
§ From a 3-week, double-blind, randomized, multicenter, placebo-controlled study of 168 patients with psoriasis.1
ll Day 21 of treatment.1
The combined score for erythema, skin thickening, and scaling, which were each evaluated on a scale of 0 (not present) to 3 (severe).1
# Days 7 and 21 of treatment.1
* From a 2-week, double-blind, randomized, multicenter, placebo-controlled study of 168 patients with atopic dermatitis (patients on Pandel®: n=106; patients on placebo: n=62).1
P<0.0001 vs placebo.1
The combined score for infiltration, scaling, erythema, lichenification, vesicles, papules, and excoriation, which were evaluated on a scale of 0 (not present) to 3 (severe).1
§ From a 3-week, double-blind, randomized, multicenter, placebo-controlled study of 168 patients with psoriasis.1
ll Day 21 of treatment.1
The combined score for erythema, skin thickening, and scaling, which were each evaluated on a scale of 0 (not present) to 3 (severe).1
# Days 7 and 21 of treatment.1
References: 1. Data on file, PharmaDerm. 2. Pandel® [Prescribing Information, 2017]. Melville, NY: PharmaDerm, a division of Fougera Pharmaceuticals Inc. 3. Clark C. Atopic eczema management. Clin Pharmacist. 2010;2:291-298. 4. Clark C. How to choose a suitable emollient. Pharm J. 2004;273:351-352.

Important Safety Information

This medication is for topical use only. Avoid contact with the eyes. The treated skin area should not be bandaged or otherwise covered or wrapped so as to be occlusive, unless directed by the physician. Therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, contact the physician.

PANDEL can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency during or after treatment. High potency corticosteroids, large treatment surface area, prolonged use, use of occlusive dressings, altered skin barrier, liver failure, and young age may predispose patients to HPA axis suppression. Use of topical corticosteroids may require periodic evaluation for HPA axis suppression. Modify use if HPA axis suppression develops. Cushing’s syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids. Pediatric patients may be more susceptible to systemic toxicity.

Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation, as observed with most topical products not containing corticosteroids. If irritation develops, discontinue PANDEL and institute appropriate therapy.

There is no clinical information on PANDEL use in pregnant women. However, animal reproduction studies showed that it can be teratogenic. There is no information on the presence of PANDEL in breast milk, or on its effects on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PANDEL and any potential adverse effects on the breastfed infant from PANDEL or from the underlying maternal condition.

The most frequent adverse reactions include burning, stinging, rash, papulovesicular rash, redness, itching, moderate paresthesia, and contact dermatitis. Local adverse reactions that have been reported with topical corticosteroids include itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infections, skin atrophy, striae, and miliaria.

Indication

PANDEL® (hydrocortisone probutate) Cream, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 18 years of age or older.

See Full Prescribing Information for Pandel®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Important Safety Information

This medication is for topical use only. Avoid contact with the eyes. The treated skin area should not be bandaged or otherwise covered or wrapped so as to be occlusive, unless directed by the physician. Therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, contact the physician.

PANDEL can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency during or after treatment. High potency corticosteroids, large treatment surface area, prolonged use, use of occlusive dressings, altered skin barrier, liver failure, and young age may predispose patients to HPA axis suppression. Use of topical corticosteroids may require periodic evaluation for HPA axis suppression. Modify use if HPA axis suppression develops. Cushing’s syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids. Pediatric patients may be more susceptible to systemic toxicity.

Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation, as observed with most topical products not containing corticosteroids. If irritation develops, discontinue PANDEL and institute appropriate therapy.

There is no clinical information on PANDEL use in pregnant women. However, animal reproduction studies showed that it can be teratogenic. There is no information on the presence of PANDEL in breast milk, or on its effects on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PANDEL and any potential adverse effects on the breastfed infant from PANDEL or from the underlying maternal condition.

The most frequent adverse reactions include burning, stinging, rash, papulovesicular rash, redness, itching, moderate paresthesia, and contact dermatitis. Local adverse reactions that have been reported with topical corticosteroids include itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infections, skin atrophy, striae, and miliaria.

Indication

PANDEL® (hydrocortisone probutate) Cream, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 18 years of age or older.

See Full Prescribing Information for Pandel®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.
CLICK TO VIEW SITE

Important Safety Information

This medication is for topical use only. Avoid contact with the eyes. The treated skin area should not be bandaged or otherwise covered or wrapped so as to be occlusive, unless directed by the physician. Therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, contact the physician.

PANDEL can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency during or after treatment. High potency corticosteroids, large treatment surface area, prolonged use, use of occlusive dressings, altered skin barrier, liver failure, and young age may predispose patients to HPA axis suppression. Use of topical corticosteroids may require periodic evaluation for HPA axis suppression. Modify use if HPA axis suppression develops. Cushing’s syndrome, hyperglycemia, and unmasking of latent diabetes mellitus can also result from systemic absorption of topical corticosteroids. Pediatric patients may be more susceptible to systemic toxicity.

Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation, as observed with most topical products not containing corticosteroids. If irritation develops, discontinue PANDEL and institute appropriate therapy.

There is no clinical information on PANDEL use in pregnant women. However, animal reproduction studies showed that it can be teratogenic. There is no information on the presence of PANDEL in breast milk, or on its effects on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for PANDEL and any potential adverse effects on the breastfed infant from PANDEL or from the underlying maternal condition.

The most frequent adverse reactions include burning, stinging, rash, papulovesicular rash, redness, itching, moderate paresthesia, and contact dermatitis. Local adverse reactions that have been reported with topical corticosteroids include itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infections, skin atrophy, striae, and miliaria.

Indication

PANDEL® (hydrocortisone probutate) Cream, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 18 years of age or older.

See Full Prescribing Information for Pandel®.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.